61/1537/2026 - Zolbetuximab Medications

This tender, identified by reference number 61/1537/2026, is for the procurement of Zolbetuximab medications. Zolbetuximab is a targeted therapy drug, specifically a monoclonal antibody, used in the treatment of certain types of cancer, particularly gastric cancer. This procurement is likely for a healthcare provider, hospital, or pharmaceutical distributor that requires this specialized medication for patient treatment. The tender documents will specify the required quantities, dosage forms, packaging, and delivery timelines for Zolbetuximab. It is crucial for the procuring entity to ensure a reliable supply of this advanced therapeutic agent. The procurement process will focus on evaluating bidders' capacity to supply authentic, high-quality Zolbetuximab that meets all regulatory and clinical standards. Factors such as product availability, pricing, and adherence to strict pharmaceutical handling and distribution protocols will be key considerations. This tender ensures access to vital cancer treatment for patients.

This is a supplies contract in the health and medical services, information and communication technology and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 203,503.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.